Table 3.

Risk of prostate cancer recurrence/progression by SLCO2B1 and SLCO1B3 SNP genotypes in a population-based prostate cancer cohorta

 SNPGenotypeRecurrence/progressionHR (95% CI)b
No (n = 326)Yes (n = 143)
SLCO2B1rs12422149GG254 (69.2)113 (30.8)1.00 (referent)
GA + AA47 (66.2)24 (33.8)1.09 (0.68–1.75)
SLCO2B1rs949069GG216 (69.5)95 (30.6)1.00 (referent)
GA + AA87 (66.4)44 (33.6)1.19 (0.82–1.73)
SLCO2B1rs2712819AA194 (70.6)81 (29.5)1.00 (referent)
AG + GG109 (65.7)57 (34.3)1.35 (0.95–1.91)
SLCO2B1rs2851069CC116 (70.3)49 (29.7)1.00 (referent)
CT + TT184 (66.9)91 (33.1)1.31 (0.92–1.89)
SLCO2B1rs7947726GG259 (69.1)116 (30.9)1.00 (referent)
AG + AA44 (67.7)21 (32.3)1.21 (0.75–1.95)
SLCO1B3rs4149117GG221 (68.0)104 (32.0)1.00 (referent)
GT + TT84 (70.0)36 (30.0)0.85 (0.57–1.26)
SLCO1B3rs3829311GG206 (68.0)97 (32.0)1.00 (referent)
GA + AA98 (69.5)43 (30.5)0.83 (0.57–1.21)
SLCO1B3rs4762803CC239 (68.3)111 (31.7)1.00 (referent)
CG + GG66 (70.2)28 (29.8)0.86 (0.56–1.32)
  • aRecurrence/progression data available for 469 cases, variable number of cases due to failed genotyping.

  • bAdjusted for age, PSA at diagnosis, Gleason score, tumor stage, primary treatment, BMI, and smoking status.